193 related articles for article (PubMed ID: 38516890)
1. Transient inhibition of sodium-glucose cotransporter 2 after ischemia/reperfusion injury ameliorates chronic kidney disease.
Martínez-Rojas MÁ; Balcázar H; González-Soria I; González-Rivera JM; Rodríguez-Vergara ME; Velazquez-Villegas LA; León-Contreras JC; Pérez-Villalva R; Correa F; Rosetti F; Bobadilla NA
JCI Insight; 2024 Feb; 9(6):. PubMed ID: 38516890
[TBL] [Abstract][Full Text] [Related]
2. A short treatment with resveratrol after a renal ischaemia-reperfusion injury prevents maladaptive repair and long-term chronic kidney disease in rats.
Martínez-Rojas MÁ; Balcázar H; Ponce-Nava MS; González-Soria I; Marquina-Castillo B; Pérez-Villalva R; Bobadilla NA
J Physiol; 2024 Apr; 602(8):1835-1852. PubMed ID: 38529522
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy.
Oe Y; Kim YC; Sidorenko VS; Zhang H; Kanoo S; Lopez N; Goodluck HA; Crespo-Masip M; Vallon V
Am J Physiol Renal Physiol; 2024 Feb; 326(2):F227-F240. PubMed ID: 38031729
[TBL] [Abstract][Full Text] [Related]
4. Doxazosin down-regulates sodium-glucose cotransporter-2 and exerts a renoprotective effect in rat models of acute renal injury.
Rezq S; Nasr AM; Shaheen A; Elshazly SM
Basic Clin Pharmacol Toxicol; 2020 May; 126(5):413-423. PubMed ID: 31788938
[TBL] [Abstract][Full Text] [Related]
5. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
[TBL] [Abstract][Full Text] [Related]
6. RNA-Seq transcriptome analysis of renal tissue from spontaneously hypertensive rats revealed renal protective effects of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2.
Wei J; Tan F; Long X; Fang Q; Wang Y; Wang J; He J; Yuan X; Du J
Eur J Pharm Sci; 2023 Oct; 189():106531. PubMed ID: 37479045
[TBL] [Abstract][Full Text] [Related]
7. Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients.
Cai D; Chen Q; Mao L; Xiao T; Wang Y; Gu Q; Wang Q; Ji Y; Sun L
Eur J Clin Pharmacol; 2024 Apr; 80(4):613-620. PubMed ID: 38319348
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time?
Hasegawa S; Nangaku M
Kidney Int; 2022 Jan; 101(1):20-22. PubMed ID: 34991813
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Sodium-Glucose Cotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease.
Rodriguez D; Kapoor S; Edenhofer I; Segerer S; Riwanto M; Kipar A; Yang M; Mei C; Wüthrich RP
Kidney Blood Press Res; 2015; 40(6):638-47. PubMed ID: 26698317
[TBL] [Abstract][Full Text] [Related]
10. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
Mima A
Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
[TBL] [Abstract][Full Text] [Related]
11. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
Zhang Y; Nakano D; Guan Y; Hitomi H; Uemura A; Masaki T; Kobara H; Sugaya T; Nishiyama A
Kidney Int; 2018 Sep; 94(3):524-535. PubMed ID: 30045814
[TBL] [Abstract][Full Text] [Related]
12. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
13. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
[TBL] [Abstract][Full Text] [Related]
14. Reduced
Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
[TBL] [Abstract][Full Text] [Related]
15. Effect of NAD+ boosting on kidney ischemia-reperfusion injury.
Morevati M; Egstrand S; Nordholm A; Mace ML; Andersen CB; Salmani R; Olgaard K; Lewin E
PLoS One; 2021; 16(6):e0252554. PubMed ID: 34061900
[TBL] [Abstract][Full Text] [Related]
16. Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation.
Barrera-Chimal J; Rocha L; Amador-Martínez I; Pérez-Villalva R; González R; Cortés-González C; Uribe N; Ramírez V; Berman N; Gamba G; Bobadilla NA
Nephrol Dial Transplant; 2019 May; 34(5):794-801. PubMed ID: 30107561
[TBL] [Abstract][Full Text] [Related]
17. NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injury.
Xie ZY; Dong W; Zhang L; Wang MJ; Xiao ZM; Zhang YH; Shi WX; Huang Y; Yang Y; Li CL; Fu L; Zhao XC; Li RZ; Li ZL; Chen YH; Ye ZM; Liu SX; Dong Z; Liang XL
Acta Pharmacol Sin; 2022 Aug; 43(8):2081-2093. PubMed ID: 34937917
[TBL] [Abstract][Full Text] [Related]
18. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
19. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling.
Zhang Y; Lin X; Chu Y; Chen X; Du H; Zhang H; Xu C; Xie H; Ruan Q; Lin J; Liu J; Zeng J; Ma K; Chai D
Cardiovasc Diabetol; 2021 Jun; 20(1):121. PubMed ID: 34116674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
